Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2021

	2021
Valuation assumptions
Expected dividend yield		0.0	%
Expected volatility		70.0% – 123.0	%
Expected term (years) – simplified method		5.5 – 6.1
Risk-free interest rate		0.95% – 1.16	%

Stock option activity during the nine-month periods ended September, 2021 and 2020 is as follows:

Schedule of Share Option Activity

	Number of Options			Weighted average exercise price		Weighted average remaining contractual term
Balance as of January 1, 2020		509,173		$	1.30		7.4
Granted		505,726			2.01
Exercised		(59,909	)		2.00
Forfeited		(33,756	)		2.00
Expired		(155,110	)		1.04
Balance as of September 30, 2020		766,124		$	1.77		7.8
Exercisable as of September 30, 2020		345,421		$	1.22		6.9

Balance as of January 1, 2021		756,383		$	1.82		8.7
Granted		1,280,939			4.54
Additional options to StemoniX option holders		191,880			4.61
Options assumed in Merger		55,840			45.95
Exercised		(29,916	)		1.24
Forfeited		(91,084	)		3.82
Expired		(11,204	)		1.45
Balance as of September 30, 2021		2,152,838		$	4.76		8.8
Exercisable as of September 30, 2021		612,132		$	5.73		7.5

The Company recognized stock-based compensation related to different instruments for the three and nine months ended September 30 as follows:


	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
Stock Options	$	287	$	73	$	1,005	$	170
Shares issued for services		10		34		20		156
Total	$	297	$	107	$	1,025	$	326